Replies to post #195819 on Biotech Values

[exwannabe]

FDA approves Opdivo for second-line non-squamous NSCLC:

And nothing at all about the less than stellar (PD-L1 expression) subset data.

I doubt anybody can question what the new SOC is.

[DewDiligence]

FDA approves Dako’s PD-L1 test for use with Opdivo, although the Opdivo FDA label does not require use of a companion diagnostic:

http://finance.yahoo.com/news/dako-agilent-technologies-company-announces-192100979.html

Note: Dako’s PD-L1 test for Opdivo is not exactly the same as its PD-l1 test for Keytruda (#msg-117555993).